RenovoRx (NASDAQ: RNXT) details results and strategy in new update

Rhea-AI Filing Summary

RenovoRx, Inc. filed a current report stating that on August 14, 2025 it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company also used the press release to share updates on its clinical trial and commercialization strategy.

The press release is included as Exhibit 99.1 to the report and is incorporated by reference, meaning the detailed financial figures and strategic updates are provided in that exhibit rather than in the body of the report.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001574094 0001574094 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

RENOVORX, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40738		27-1448452
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2570 W El Camino Real, Suite 320 Mountain View, CA				94040
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (650) 284-4433

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		RNXT		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01 Other Events.

In addition to announcing certain financial results, the Company’s press release provides certain updates of the Company’s clinical trial and commercialization strategy described in such press release. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of RenovoRx, Inc., dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RENOVORX, INC.
Date: August 14, 2025
	By:	/s/ Shaun R. Bagai
	Name:	Shaun R. Bagai
	Title:	Chief Executive Officer

-3-

FAQ

What did RenovoRx (RNXT) disclose in its latest 8-K filing?

RenovoRx disclosed that it issued a press release on August 14, 2025 announcing financial results for the quarter ended June 30, 2025 and providing updates on its clinical trial and commercialization strategy.

Which period do the latest RenovoRx (RNXT) financial results cover?

The financial results referenced in the filing cover RenovoRx’s performance for the quarter ended June 30, 2025.

Where can investors find the detailed RenovoRx (RNXT) financial results and strategy updates?

The detailed financial results and updates are contained in the press release attached as Exhibit 99.1 to the report and incorporated by reference.

Does the RenovoRx (RNXT) filing mention clinical trial progress?

Yes. The filing states that the press release includes updates on RenovoRx’s clinical trial and its commercialization strategy.

Who signed the RenovoRx (RNXT) 8-K report?

The report was signed on behalf of RenovoRx, Inc. by Shaun R. Bagai, its Chief Executive Officer.